Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2019.
Starpharma’s cash balance as at 30 September 2019 was $36.8 million, with net operating cash outflows for the quarter of $4.6 million. The cash balance does not include the anticipated $4.9 million R&D tax incentive which is expected to be received during the December quarter.
Starpharma today announced that it has been invited once more to present at the 9th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 7-8 October.
The PODD conference showcases the latest advances in drug delivery and provides networking opportunities with senior scientific and commercial executives from many of the major international pharmaceutical companies. This year’s PODD conference will be chaired by AstraZeneca’s Head of Drug Delivery, Dr Shawn Davis.
Starpharma today announced that that the U.S. Food and Drug Administration (FDA) has authorised the use of AstraZeneca’s DEP® Bcl2/xL conjugate AZD0466 in clinical trials under an investigational new drug (IND) application. This is the first DEP® candidate to reach this milestone from Starpharma’s multiproduct license with AstraZeneca.
Finance News Network reported Starpharma received further regulatory approval in another Asian country for its breakthrough product for bacterial vaginosis, VivaGel® BV. The news follows the first approval in the region announced on 15 August.
Online news outlet Boardroom Media interviewed Starpharma CEO Dr Jackie Fairley following the release of its annual report and full-year results. In the interview, Dr Fairley shared the company’s latest DEP® trial results, as well as VivaGel® and upcoming milestones.
Online investor news outlet Finance News Network reported Starpharma’s positive results for its novel HER-2 targeted DEP® conjugate (ADC) which outperformed the leading HER-2 ADC, Kadcyla®, in a human ovarian cancer model.
Biotech trade publication noted Starpharma announced promising efficacy signals in its ongoing clinical trials for both DEP® cabazitaxel and DEP® docetaxel.
